Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity

被引：55

作者：

Acuña G. ^{[1
]}

Foernzler D. ^{[1
]}

Leong D. ^{[2
]}

Rabbia M. ^{[1
]}

Smit R. ^{[1
]}

Dorflinger E. ^{[1
]}

Gasser R. ^{[1
]}

Hoh J. ^{[3
]}

Ott J. ^{[3
]}

Borroni E. ^{[1
]}

To Z. ^{[1
]}

Thompson A. ^{[1
]}

Li J. ^{[2
]}

Hashimoto L. ^{[1
]}

Lindpaintner K. ^{[1
]}

机构：

[1] F. Hoffman-La Roche Ltd., Basel

[2] Roche Molecular Systems Inc., Alameda, CA

[3] Laboratory of Statistical Genetics, The Rockefeller University, Rockefeller, NY

来源：

The Pharmacogenomics Journal | 2002年 / 2卷 / 5期

关键词：

Hepatotoxicity; Pharmacogenetics; Tolcapone; UDP-glucuronosyl transferase 1; UGT1A;

D O I：

10.1038/sj.tpj.6500123

中图分类号：

学科分类号：

摘要：

A retrospective pharmacogenetic study was conducted to identify possible genetic susceptibility factors in patients in whom the administration of the anti-Parkinson drug, tolcapone (TASMAR®), was associated with hepatic toxicity. We studied 135 cases of patients with elevated liver transaminase levels (ELT) of ≥ 1.5 times above the upper limit of normal, in comparison with matched controls that had also received the drug but had not experienced ELT. DNA samples were genotyped for 30 previously described or newly characterized bi-allelic single nucleotide polymorphisms (SNPs), representing 12 candidate genes selected based on the known metabolic pathways involved in the tolcapone elimination. SNPs located within the UDP-glucuronosyl transferase 1A gene complex, which codes for the enzymes involved in the main elimination pathway of the drug, were found to be significantly associated with the occurrence of tolcapone-associated ELTs.

引用

页码：327 / 334

页数：7

共 14 条

[1] Olanow C.W., Tolcapone and hepatotoxic effects, Arch. Neurol., 57, pp. 263-267, (2000)
[2] Spahr L., Rubbia-Brandt L., Burkhard P.R., Assal F., Hadengue A., Tolcapone-related fulminant hepatitis, Dig. Dis. Sci., 45, pp. 1881-1884, (2000)
[3] Assal F., Spahr L., Hadengue A., Rubbici-Brandt L., Burkhard P.R., Tolcapone and fulminant hepatitis, Lancet, 352, (1998)
[4] Schlappi B., Morimoto H., Kobayashi K., Horii I., Six-month oral toxicity study with tolcapone on beagle dogs, Jpn. Pharmacol. Ther., 24, SUPPL., pp. 77-102, (1996)
[5] Schlappi B., Jovanovic D., Okada M., Kobayashi K., Horii I., Six-month oral toxicity study of tolcapone in rat (feed admix), Jpn. Pharmacol. Ther., 24, SUPPL., pp. 49-75, (1996)
[6] Jorga K., Fotteler B., Heizmann P., Gasser R., Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase, Br. J. Clin. Pharmacol., 4, pp. 513-520, (1999)
[7] Clark A.G., Inference of haplotypes from PCR-amplified samples of diploid populations, Mol. Biol. Evol., 111, (1990)
[8] Ciotti M., Marrone A., Potter C., Owens I.S., Genetic polymorphisms in the human UGT1A6 (planar phenol) UDP-glucuronosyl-transferase: Pharmacological implications, Pharmacogenetics, 7, pp. 485-495, (1997)
[9] Di Paola R., Frittitta L., Miscio G., Bozzali M., Baratta R., Centra M., Et al., A variation in 3′UTR of hPTP1B increases specific gene expression and associates with insulin resistance, Am. J. Hum. Genet., 70, pp. 806-812, (2002)
[10] Lehnert V., Holzwarth J., Ott M., Thompson A., Demmak S., Foernzler D., A semi-automated system for analysis and storage of SNPs, Hum. Mutat., 17, pp. 243-254, (2001)

← 1 2 →